



FACULTÉ  
DE MÉDECINE

UNIVERSITÉ LIBRE DE BRUXELLES

# Involvement of High Mobility Group Box 1 protein in acetaminophen-induced liver injury : dissection of signaling pathways and potential therapeutic targeting.

**Thesis submitted by Charlotte MINSART**

**in fulfilment of the requirements of the PhD Degree in “Docteur en Sciences  
Biomédicales et Pharmaceutiques”**

**Academic year 2020-2021**

Supervisor: Pr Thierry Gustot

Co-supervisor: Pr Jacques Devière

*Laboratoire de Gastro-entérologie Expérimentale*

## **Thesis jury:**

Pr Alain LE MOINE (President)

Pr Thierry GUSTOT (Supervisor and Secretary)

Pr Jacques DEVIÈRE (Co-supervisor)

Pr Véronique FLAMAND

Pr Philippe GOYENS

Pr Jean-Yves SPRINGAEL

Pr Nicolas LANTHIER (Université Catholique de Louvain)

Pr Abdellah MANSOURI (Université Paris Diderot)



# Table of contents

---

<b>Abbreviations</b>	<b>9</b>
<b>General Introduction</b>	<b>11</b>
<b>1. Acetaminophen</b>	<b>12</b>
1.1 Acetaminophen : history	12
1.2 Acetaminophen: first overdose reports	13
1.3 Acetaminophen overdose : Epidemiology	14
1.4 Acetaminophen-induced hepatotoxicity	16
1.4.1 APAP-adducts	17
1.4.2 Mitochondrial dysfunction	18
1.4.3 Hepatocyte death	19
1.4.4 Inflammatory response	22
1.4.5 Damage-Associated Molecular Pattern's (DAMPs)	24
1.4.5.1 DAMPs and inflammasome activation	26
1.4.5.2 DAMPs and inflammatory response	25
1.5 Treatments and limitations	28
<b>2. High Mobility Group Box 1 protein</b>	<b>30</b>
2.1 Discovery	30
2.2 Properties	30
2.3 Structure	31
2.4 Nuclear functions	32
2.5 Post-translational modifications	33
2.6 Extracellular functions	34
2.7 HMGB1 as inflammatory DAMP	36
2.7.1 Receptors mediating HMGB1 activity	37
2.7.2 Redox state and cytokine activity of HMGB1	39
<b>3. Role of HMGB1 in acetaminophen hepatotoxicity</b>	<b>41</b>
3.1 HMGB1 and liver injury	41
3.1.1 HMGB1 as biomarker of APAP-induced liver injury	41
3.1.2 HMGB1 inhibitors	41
3.1.3 HMGB1 and inflammasome	42
3.2 HMGB1 and liver repair	43
<b>4. Aims of the project</b>	<b>44</b>
<b>Results</b>	<b>45</b>
<b>1. Role of HMGB1 in a murine model of APAP-induced liver injury</b>	<b>46</b>
1.1 Introduction	46
1.2 Materials and methods	47
1.3 Results	51
1.3.1 Murine model of APAP-induced liver injury	51

1.3.2 Inflammatory cytokines and APAP-induced liver injury-----	51
1.3.3 Release of HMGB1 during APAP-induced liver injury -----	52
1.3.4 Glycyrrhizin protects mice against APAP hepatotoxicity -----	53
1.3.5 Hepatic expression of HMGB1 receptors during APAP-induced liver injury -----	55
1.3.6 APAP-induced liver injury is exacerbated in absence of Kupffer cells-----	56
1.3.7 Absence of neutrophil recruitment during APAP-induced liver injury -----	58
1.3.8 APAP-induced liver injury is exacerbated in TLR4-deficient mice -----	59
1.4 Key findings-----	61
<b>2. HMGB1-driven feed-forward hepatocyte TLR4/TRIF/RIPK3-dependent necrosis circuit in acetaminophen-induced liver injury -----</b>	<b>63</b>
2.1 Introduction-----	63
2.2 Materials and methods-----	64
2.3 Results -----	68
2.3.1 HMGB1 is released by APAP-damaged hepatocytes -----	68
2.3.2 HMGB1 amplifies by itself APAP-induced hepatocyte death-----	69
2.3.3 HMGB1 and APAP induce hepatocytes necroptosis by RIPK3-dependent pathway -----	73
2.3.4 Implication of proteins mediated necroptosis signaling downstream of RIPK3-----	78
2.3.6 Contribution of the TLR3/4 adaptor TRIF to APAP-induced hepatocyte injury -----	83
2.3.7 HepaRG cells and HMGB1 receptors-----	84
2.3.8 TLR4 blockade protects HepaRG cell death induced by rhHMGB1 and APAP-----	85
2.3.9 CYP3A4 and CYP2E1 activity were not influenced by drugs used in our experiments -----	86
2.4 Key findings-----	88
<b>3. Combination of glycyrrhizin and N-acetylcysteine: benefit outcome in a murine model of acetaminophen-induced liver failure-----</b>	<b>90</b>
3.1 Introduction-----	90
3.2 Materials and Methods-----	91
3.3 Results -----	94
3.3.1 Administration of GL, at the same time as APAP, reduces the severity of liver injury-----	94
3.3.2 Administration of NAC/GL combination, at the same time as APAP, reduces the severity of liver injury as well as GL or NAC alone-----	95
3.3.3 Delayed administration of NAC/GL combination reduces APAP-induced hepatocytes necrosis compared to GL or NAC alone -----	98
3.3.4 Delayed administration of NAC/GL combination increases mice survival following APAP-induced liver injury compared to GL or NAC alone-----	101
3.3.5 Protective effects of the NAC/GL combination do not result from inhibition of hepatic expression of CYP2E1 -----	102
3.3.6 Protective effects of the NAC/GL combination are not gender-dependent -----	103
3.4 Key Findings-----	105
<b>Discussion-----</b>	<b>106</b>
<b>1. Role of HMGB1 in a murine model of APAP-induced liver injury -----</b>	<b>107</b>
<b>2. HMGB1-driven feed-forward hepatocyte TLR4/TRIF/RIPK3-dependent necrosis circuit in acetaminophen-induced liver injury -----</b>	<b>109</b>
<b>3. Combination of glycyrrhizin and N-acetylcysteine: benefit outcome in a murine model of acetaminophen-induced liver failure-----</b>	<b>111</b>

<b>General conclusion</b>	<b>-113</b>
<b>Perspectives</b>	<b>-115</b>
1.HMGB1 silencing	116
2. HMGB1 and post-translational states	118
3. HMGB1 likes company	120
4. TLR4: deleterious or protective role?	121
<b>References</b>	<b>-122</b>
<b>Appendix</b>	<b>-143</b>
<b>Annex A: List and sequences of primers used for PCR analysis</b>	<b>144</b>
<b>Annex B: Criteria used for evaluation of necrosis score</b>	<b>146</b>
<b>Annex C: List of publications</b>	<b>147</b>
1. Publications related to this thesis	147
1.1 Peer-reviewed journal articles	147
1.2 Peer-reviewed conference abstracts	147
2. Publications unrelated to this thesis	148
Peer-reviewed journal articles	148